Startseite>>Signaling Pathways>> Microbiology & Virology>> SARS-CoV>>Nelfinavir

Nelfinavir

Katalog-Nr.GC17709

Nelfinavir (AG-1341) ist ein potenter und oral bioverfÜgbarer HIV-1-Protease-Inhibitor (Ki=2 nM) fÜr die HIV-Infektion.

Products are for research use only. Not for human use. We do not sell to patients.

Nelfinavir Chemische Struktur

Cas No.: 159989-64-7

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
124,00 $
Auf Lager
2mg
54,00 $
Auf Lager
5mg
99,00 $
Auf Lager
10mg
149,00 $
Auf Lager
50mg
342,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Nelfinavir (AG-1341) is a potent and orally bioavailable HIV-1 protease inhibitor (Ki=2 nM) and antiviral agent for the treatment of HIV infection. Nelfinavir is a broad-spectrum, anticancer agent[1][2][3].

References:
[1]. Mondal D, et al. Nelfinavir suppresses insulin signaling and nitric oxide production by human aortic endothelial cells: protective effects of thiazolidinediones. Ochsner J. 2013 Spring;13(1):76-90.
[2]. Gills JJ, et al. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that inducesendoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res. 2007 Sep 1;13(17):5183-94.
[3]. Kaldor SW, et al. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J Med Chem. 1997 Nov 21;40(24):3979-85.

Bewertungen

Review for Nelfinavir

Average Rating: 5 ★★★★★ (Based on Reviews and 24 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Nelfinavir

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.